The Government of Castilla y León approves aid of 8.5 million euros for the R&D projects of Horse, Syva and Telecyl

The Board of Directors, meeting this Thursday, declared of particular interest the strategic R&D plans of the companies Horse (Renault) of Valladolid, Laboratorios Syva of León and Telecyl of Valladolid and approves aid worth 8,421 euros with a commercial investment. in the new strategic plans of 22,643,840 euros.

The Minister of Economy and Finance and spokesperson, Carlos Fernández Carriedo, explained during the press conference that followed that the regional executive had approved a grant worth 6,089,849 euros for the Horse automobile company and had declared six strategic plans of special interest to promote the technology. to offer technological solutions to facilitate the transition to a more responsible and sustainable future mobility, in areas such as energy efficiency, data technology and artificial intelligence, automation, hydrogen use and automationamong other aspects.

The Horse Community Work Centers will become, based on the knowledge that will be generated in the R&D projects presented, a center for developing new mobility solutions.

The six strategic plans presented by HORSE, which involves an investment of 15,859,827 euros, They are structured around the following projects: technological development for a high-pressure casting process; digitalization for the energy transition; development of new solutions based on artificial vision, IOT AI; electrified vehicle parts development process; hydrogen combustion technologies; and finally, new alloys for electric vehicles.

These R&D plans presented by the company provide for an increase in personnel in the areas of R&D, the realization of a private investment in its two work centers in Castilla y León for the three-year period 2024-2026 which will reach 150 million eurosand subcontracting with the CARTIF technology centers for an amount of 150,000 euros and with ITCL for 110,000 euros.

Horse Spain, owned by Renault, has more than 9,000 employees spread across eight factories and three R&D&i centers, with a global presence in seven countries (Argentina, Brazil, Chile, Spain, Portugal, Romania and Turkey). In Spain it has the R&D center in Valladolid, the engine factory also in this city, the gearbox and transmission factory in Seville and the head office in Alcobendas (Madrid). Work centers in which more than 3,600 professionals carry out their activity on the path to more responsible mobility.

Syva Veterinary Laboratories

The Council also approved a grant amounting to 1,534,720 euros to SYVA Laboratories and declared its strategic R&D plan of Special Interest to develop new veterinary medicines in 3 areas of work: a new inactivated vaccine against porcine pathogens; a biotherapeutic product, also intended for the pig industry; and new immunological products for pets. SYVA’s strategic plan involves a commercial investment of 3,594,745 euros

In terms of employment, the Strategic Plan estimates create 13 new jobs in R&D activities and the subsequent industrialization of the results of innovation processes. This also means the stability of the current 269 workers, as well as the tractor effect in the region. Regarding associated investments, the company estimates that R&D expenses exceed 10 million euros and that 20 million will be invested in the industrialization phase of the results.

In addition, Syva Laboratories has an annual collaboration contract with the University of León, linked to the exchange of information and the use of the necessary means to undertake the projects included in the Strategic Plan. Located in Léon, It has two production plants dedicated to the manufacture of veterinary specialties and pharmaceutical products.

It has a manufacturing plant in Trobajo del Camino (León) dedicated to the manufacture of pharmacological products, among which sterile injectable products, sterile intramammary ointments, oral products and tablets stand out.

The new manufacturing plant located in the León Technological Park is dedicated exclusively to the manufacture of immunological products, both viral and bacterial, and in this factory there are also the biological R&D and immunological quality control departments. The company has 291 workers and 20 people in the R&D department.

Telecyl

The Governing Council approved a grant amounting to 797,317 euros for the company Telecyl, which presents two strategic R&D plans with an investment amounting to 3,189,268 euros. The general objective of the R&D&i Strategic Plan is to promote the adoption of innovative technologies, with a focus on Artificial Intelligence and Trusted Data Spaceswith the aim of transforming customer service services and improving the capabilities of all workers, through two lines of work:

The first project, called Contact Center 2030, aims to integrate emerging technologies to provide superior and excellent multi-channel customer service.

Through the use of artificial intelligence and virtual agents, the aim is to improve the efficiency and effectiveness of customer service, which will help strengthen the relationship with customers and increase the competitiveness of the ‘business.

The second project aims to develop digital synergies through the NextGen Workforce program, which aims to study fundamental AI models and low-power distributed ledger technologies to optimize worker efficiency and well-being and be more sustainable in operations. In terms of employment, the company estimates expected to increase by 10 new jobs in R&D activities (graduates).